ReviewMolecules (Basel, Switzerland)2024
Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets.
Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 83 citations in OpenAlex.
- Machine learning for discovering anticancer compounds from plants and elucidating their mechanisms.Journal of computer-aided molecular design · 2026Review
- Epigallocatechin Gallate Modulates the Cellular Response to Doxorubicin in HeLa Cervical Cancer Cells.Biomolecules · 2026Article
- Heavy metal toxicity as a driver of endoplasmic reticulum stress and dysfunction.The FEBS journal · 2026Review
- The Redox Paradox of Natural Supplements in Cancer: A Narrative Review to Guide Clinical Practice.Antioxidants (Basel, Switzerland) · 2026Review
- Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.The AAPS journal · 2026Review
- Plant-Derived Bioactive Compounds and Their Therapeutic Potential in Cancer.International journal of molecular sciences · 2026Review
- RHBDL2 drives lipid metabolic reprogramming in osteosarcoma via USP3-mediated deubiquitination of PPT1.Cell death & disease · 2026Article
- Next-Generation Hydrogels Integrating Natural Antioxidants and Microbiome Modulators for Improved Cancer Management.Gels (Basel, Switzerland) · 2026Review
- Novel Strategy for Cancer Therapy Proposal Based on Effects and Mechanisms of Targeting Cuproptosis by Polyphenols-A Narrative Review.Nutrients · 2026Review
- Elucidating EGCG' s targets in nasopharyngeal carcinoma through combined cell-based assays and transcriptomic sequencing.Discover oncology · 2026Article
- The potential and promise of natural antioxidants as epigenetic modulators in oral squamous cell carcinoma.Cancer chemotherapy and pharmacology · 2026Review
- The potential and promise of natural antioxidants as epigenetic modulators in oral squamous cell carcinoma.Cancer chemotherapy and pharmacology · 2026Review
- Plant-Derived Secondary Metabolites Modulating Inflammation-Driven Pathways in Hepatocellular Carcinoma: Preclinical Insights.Current issues in molecular biology · 2026Review
- Botanical Adjuvants in Oncology: A Review on Natural Compounds in Synergy with Conventional Therapies as Next-Generation Enhancers of Breast Cancer Treatment.Current issues in molecular biology · 2026Review
- Natural Products Targeting Key Molecular Hallmarks in Gastric Cancer: Focus on Apoptosis, Inflammation, and Chemoresistance.International journal of molecular sciences · 2026Review
- Green tea catechins and prostate cancer: mechanisms, clinical evidence, and safety: a narrative review.BMC cancer · 2026Review
- The Multitalented Marvels: Exploring the Versatile Potential of Natural Products in Osteosarcoma Treatment.Cancer informatics · 2026Review
- Dietary polyphenols and nutritional modulators in glioblastoma: mechanistic promise and translational barriers.Frontiers in nutrition · 2026Review
- Epigallocatechin gallate in N-methyl-N-nitrosourea-induced retinitis pigmentosa mouse model.International journal of ophthalmology · 2026Article
- Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigallocatechin gallate (EGCG) is a catechin, which is a type of flavonoid found in high concentrations in green tea. EGCG has been studied extensively for its potential health benefits, particularly in cancer. EGCG has been found to exhibit anti-proliferative, anti-angiogenic, and pro-apoptotic effects in numerous cancer cell lines and animal models. EGCG has demonstrated the ability to interrupt various signaling pathways associated with cellular proliferation and division in different cancer types. EGCG anticancer activity is mediated by interfering with various cancer hallmarks. This article summarize and highlight the effects of EGCG on cancer hallmarks and focused on the impacts of EGCG on these cancer-related hallmarks. The studies discussed in this review enrich the understanding of EGCG's potential as a therapeutic tool against cancer, offering a substantial foundation for scientists and medical experts to advance scientific and clinical investigations regarding EGCG's possibility as a potential anticancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.